Amarantus Bioscience Holdings Inc (AMBS)

[vegasvic]

Amarantus BioSciences and Banyan Biomarkers Announce Positive Data from Traumatic Brain Injury Collaboration

PR Newswire
Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF's potential as a disease-modifying agent for the treatment of TBI.

"Based on the results produced through this collaboration, we are excited about the potential of the MANF Program in generating new products to treat concussions and other forms of TBI," said Gerald Commissiong , President & CEO of Amarantus. "While this data is early on in development, we will be looking for innovative approaches to accelerate our TBI development program, while using Banyan's proprietary panel of markers as a key metric in our companion drug – diagnostic strategy."